Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
McKesson
Baxter
Mallinckrodt
Boehringer Ingelheim

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR PEGCETACOPLAN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Pegcetacoplan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02264639 ↗ A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH Completed Apellis Pharmaceuticals, Inc. Phase 1 2015-02-23 This study will be the initial exploration of pegcetacoplan in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of pegcetacoplan will guide decisions to further develop the drug.
NCT02461771 ↗ Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD Completed Apellis Pharmaceuticals, Inc. Phase 1 2015-01-28 The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for treatment of patients with AMD.
NCT02503332 ↗ Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy Completed Apellis Pharmaceuticals, Inc. Phase 2 2015-09-24 The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
NCT02588833 ↗ Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. Completed Apellis Pharmaceuticals, Inc. Phase 1 2015-12-01 The objectives of the study are to assess the safety, tolerability, preliminary efficacy and PK of multiple subcutaneous (SC) doses of pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who have not received treatment with eculizumab in the past. An exploratory objective of the study is to assess the pharmacodynamics (PD) of multiple SC doses of pegcetacoplan when administered to PNH patients.
NCT03465709 ↗ Pegcetacoplan (APL-2) in Neovascular AMD Terminated Apellis Pharmaceuticals, Inc. Phase 1/Phase 2 2018-02-14 Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pegcetacoplan

Condition Name

Condition Name for Pegcetacoplan
Intervention Trials
Geographic Atrophy 3
Complement 3 Glomerulopathy (C3G) 2
Membranoproliferative Glomerulonephritis 2
PNH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pegcetacoplan
Intervention Trials
Hemoglobinuria, Paroxysmal 6
Hemoglobinuria 6
Macular Degeneration 5
Atrophy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pegcetacoplan

Trials by Country

Trials by Country for Pegcetacoplan
Location Trials
United States 124
Australia 17
Spain 7
New Zealand 6
Japan 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pegcetacoplan
Location Trials
California 11
Florida 8
Georgia 7
Maryland 7
Texas 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pegcetacoplan

Clinical Trial Phase

Clinical Trial Phase for Pegcetacoplan
Clinical Trial Phase Trials
Phase 3 7
Phase 2 7
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pegcetacoplan
Clinical Trial Phase Trials
Completed 5
Active, not recruiting 4
Recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pegcetacoplan

Sponsor Name

Sponsor Name for Pegcetacoplan
Sponsor Trials
Apellis Pharmaceuticals, Inc. 16
Swedish Orphan Biovitrum 2
Roswell Park Cancer Institute 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pegcetacoplan
Sponsor Trials
Industry 18
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Mallinckrodt
Baxter
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.